Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: A retrospective study

Singapore Medical Journal

Volumn 54, Issue 5, 2013, Pages 263-266

  Alam, Sartaj ^a,b   Hussain, Asrar ^b   Daiwajna, Rajendra ^b   Tan, Jackson ^b  

^a Suri Seri Begawan Hospital   (Brunei Darussalam)

^b RIPAS HOSPITAL   (Brunei Darussalam)

Author keywords

Calcium based binders; Dialysis; Phosphate binders; Renagel; Sevelamer

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE BINDING AGENT; SEVELAMER; CHELATING AGENT; PHOSPHATE; POLYAMINE; URIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY FAILURE; MALE; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; URIC ACID BLOOD LEVEL; BLOOD; BONE DISEASE; CHEMISTRY; COMPLICATION; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; BONE DISEASES; CHELATING AGENTS; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; POLYAMINES; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URIC ACID;

EID: 84878216411     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: 10.11622/smedj.2013105     Document Type: Article

References (22)

1. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 2006; 70:351-7.
2. Block GA, Port FK. Re-evaluation of risk associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000; 35:1226-37.
3. Kuhlmann MK. Management of hyperphosphatemia. Hemodial Int 2006; 10:338-45.
4. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17:340-5.
5. Mudge DW Johnson DW, Hawley CM, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 2011; 12:20.
6. Hutchinson AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011; 7:578-89.
7. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245-52.
8. Qunibi W Moustafa M, Muenz LR, et al. A 1 year randomised trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51:952-65.
9. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815-24.
10. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71:438-41.
11. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72:1255-61.
12. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51:445-54.
13. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. Arthritis Rheum 2005; 52:290-5.
14. Shantouf R, Budoff MJ, Ahmadi N, et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 2008; 28:275-9.
15. Ferramosca E, Burke S, Chasan-Taber S, et al.: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149:820-5.
16. Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med 2009; 48:415-20.
17. Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 2004; 25:785-91.
18. Lieu YL, Lin HH, Yu CC, et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail 2006; 28:701-7.
19. Chow KM, Szeto CC, Kwan BC, Leung CB, Li PK. Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources. J Nephrol 2007; 20:674-82.
20. Lo WK, Cheng SW, Ng SY, et al. Efficacy and side effects of sevelamer hydrochloride as sole phosphate binder in peritoneal dialysis patients with severe hyperphosphatemia. Perit Dial Int 2008; 28:93-5.
21. Gulati A, Sridhar V, Bose T, Hari P, Bagga A. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. Int Urol Nephrol 2010; 42:1055-62.
22. Lin YF, Chen YM, Hung KY, et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. J Formos Med Assoc 2010; 109:663-72.